{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:25:48Z","timestamp":1784085948796,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001825","name":"Danish Agency for Science and Higher Education","doi-asserted-by":"publisher","award":["KnowledgeBridge grant 2023"],"award-info":[{"award-number":["KnowledgeBridge grant 2023"]}],"id":[{"id":"10.13039\/501100001825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10620-025-09007-w","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T08:27:06Z","timestamp":1743236826000},"page":"2021-2031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced Colitis"],"prefix":"10.1007","volume":"70","author":[{"given":"Sidsel","family":"St\u00f8y","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Damgaard","family":"Sandahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Dige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Louise","family":"Kj\u00f8lbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"van de Bunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"9007_CR1","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms23073464","volume":"23","author":"PT Santana","year":"2022","unstructured":"Santana PT, Rosas SLB, Ribeiro BE et al. Dysbiosis in inflammatory bowel disease: pathogenic role and potential therapeutic targets. Int J Mol Sci. 2022;23:3464. https:\/\/doi.org\/10.3390\/ijms23073464.","journal-title":"Int J Mol Sci."},{"key":"9007_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","volume":"6","author":"D Alsoud","year":"2021","unstructured":"Alsoud D, Verstockt B, Fiocchi C et al. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6:589\u2013595. https:\/\/doi.org\/10.1016\/S2468-1253(21)00065-0.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9007_CR3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/ecco-jcc\/jjaa087","volume":"14","author":"B Zhang","year":"2020","unstructured":"Zhang B, Gulati A, Alipour O et al. Relapse from deep remission after therapeutic De-escalation in inflammatory bowel disease: A systematic review and meta-analysis. J Crohns Colitis. 2020;14:1413\u20131423. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa087.","journal-title":"J Crohns Colitis."},{"key":"9007_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","volume":"5","author":"V Jairath","year":"2020","unstructured":"Jairath V, Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5:2\u20133. https:\/\/doi.org\/10.1016\/S2468-1253(19)30358-9.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9007_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/mi.2013.73","volume":"7","author":"MF Neurath","year":"2014","unstructured":"Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6\u201319. https:\/\/doi.org\/10.1038\/mi.2013.73.","journal-title":"Mucosal Immunol."},{"key":"9007_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/1756283X11398930","volume":"4","author":"M Iacucci","year":"2011","unstructured":"Iacucci M, Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Ther Adv Gastroenterol. 2011;4:129\u2013143. https:\/\/doi.org\/10.1177\/1756283X11398930.","journal-title":"Ther Adv Gastroenterol."},{"key":"9007_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","volume":"159","author":"RC Ungaro","year":"2020","unstructured":"Ungaro RC, Yzet C, Bossuyt P et al. Deep remission at 1 year prevents progression of early crohn\u2019s disease. Gastroenterology. 2020;159:139\u2013147. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.039.","journal-title":"Gastroenterology."},{"key":"9007_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","volume":"14","author":"SC Shah","year":"2016","unstructured":"Shah SC, Colombel J-F, Sands BE et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:1245-1255.e8. https:\/\/doi.org\/10.1016\/j.cgh.2016.01.015.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"9007_CR9","doi-asserted-by":"publisher","first-page":"119195","DOI":"10.1016\/j.lfs.2021.119195","volume":"271","author":"L Patnaude","year":"2021","unstructured":"Patnaude L, Mayo M, Mario R et al. Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair. Life Sci. 2021;271:119195. https:\/\/doi.org\/10.1016\/j.lfs.2021.119195.","journal-title":"Life Sci."},{"key":"9007_CR10","doi-asserted-by":"publisher","first-page":"e20192195","DOI":"10.1084\/jem.20192195","volume":"217","author":"M Keir","year":"2020","unstructured":"Keir M, Yi T, Lu T et al. The role of IL-22 in intestinal health and disease. J Exp Med. 2020;217:e20192195. https:\/\/doi.org\/10.1084\/jem.20192195.","journal-title":"J Exp Med."},{"key":"9007_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrd4176","volume":"13","author":"R Sabat","year":"2014","unstructured":"Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014;13:21\u201338. https:\/\/doi.org\/10.1038\/nrd4176.","journal-title":"Nat Rev Drug Discov."},{"key":"9007_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","volume":"50","author":"W Ouyang","year":"2019","unstructured":"Ouyang W, O\u2019Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019;50:871\u2013891. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.020.","journal-title":"Immunity."},{"key":"9007_CR13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41423-018-0055-6","volume":"16","author":"B Gao","year":"2019","unstructured":"Gao B, Xiang X. Interleukin-22 from bench to bedside: a promising drug for epithelial repair. Cell Mol Immunol. 2019;16:666\u2013667. https:\/\/doi.org\/10.1038\/s41423-018-0055-6.","journal-title":"Cell Mol Immunol."},{"key":"9007_CR14","doi-asserted-by":"publisher","first-page":"e00434","DOI":"10.1002\/prp2.434","volume":"6","author":"DW Lee","year":"2018","unstructured":"Lee DW, Zhong S, Pai R et al. Nonclinical safety assessment of a human interleukin-22FC IG fusion protein demonstrates in vitro to in vivo and cross-species translatability. Pharmacol Res Perspect. 2018;6:e00434. https:\/\/doi.org\/10.1002\/prp2.434.","journal-title":"Pharmacol Res Perspect."},{"key":"9007_CR15","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s11010-023-04806-z","volume":"479","author":"H Nong","year":"2024","unstructured":"Nong H, Yuan H, Lin Y et al. IL-22 promotes occludin expression by activating autophagy and treats ulcerative colitis. Mol Cell Biochem. 2024;479:1443\u20131450. https:\/\/doi.org\/10.1007\/s11010-023-04806-z.","journal-title":"Mol Cell Biochem."},{"key":"9007_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1172\/JCI33194","volume":"118","author":"K Sugimoto","year":"2008","unstructured":"Sugimoto K, Ogawa A, Mizoguchi E et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118:534\u2013544. https:\/\/doi.org\/10.1172\/JCI33194.","journal-title":"J Clin Invest."},{"key":"9007_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2018.12.032","volume":"295","author":"R Menacho-Melgar","year":"2019","unstructured":"Menacho-Melgar R, Decker JS, Hennigan JN et al. A review of lipidation in the development of advanced protein and peptide therapeutics. J Control Release Off J Control Release Soc. 2019;295:1\u201312. https:\/\/doi.org\/10.1016\/j.jconrel.2018.12.032.","journal-title":"J Control Release Off J Control Release Soc."},{"key":"9007_CR18","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1172\/JCI72189","volume":"124","author":"S D\u2019Alessio","year":"2014","unstructured":"D\u2019Alessio S, Correale C, Tacconi C et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest. 2014;124:3863\u20133878. https:\/\/doi.org\/10.1172\/JCI72189.","journal-title":"J Clin Invest."},{"key":"9007_CR19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1053\/gast.2002.32994","volume":"122","author":"D Rachmilewitz","year":"2002","unstructured":"Rachmilewitz D, Karmeli F, Takabayashi K et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002;122:1428\u20131441. https:\/\/doi.org\/10.1053\/gast.2002.32994.","journal-title":"Gastroenterology."},{"key":"9007_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3748\/wjg.v29.i10.1539","volume":"29","author":"E Cheah","year":"2023","unstructured":"Cheah E, Huang JG. Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. World J Gastroenterol. 2023;29:1539\u20131550. https:\/\/doi.org\/10.3748\/wjg.v29.i10.1539.","journal-title":"World J Gastroenterol."},{"key":"9007_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12876-021-01883-6","volume":"21","author":"O Alipour","year":"2021","unstructured":"Alipour O, Gualti A, Shao L et al. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNF\u03b1 in inflammatory bowel disease. BMC Gastroenterol. 2021;21:312. https:\/\/doi.org\/10.1186\/s12876-021-01883-6.","journal-title":"BMC Gastroenterol."},{"key":"9007_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/jcag\/gwad032","volume":"7","author":"P Wetwittayakhlang","year":"2024","unstructured":"Wetwittayakhlang P, Lakatos PL. Current evidence for combined targeted therapy for the treatment of inflammatory bowel disease. J Can Assoc Gastroenterol. 2024;7:22\u201329. https:\/\/doi.org\/10.1093\/jcag\/gwad032.","journal-title":"J Can Assoc Gastroenterol."},{"key":"9007_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.immuni.2008.11.003","volume":"29","author":"LA Zenewicz","year":"2008","unstructured":"Zenewicz LA, Yancopoulos GD, Valenzuela DM et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 2008;29:947\u2013957. https:\/\/doi.org\/10.1016\/j.immuni.2008.11.003.","journal-title":"Immunity."},{"key":"9007_CR24","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3390\/cells9102205","volume":"9","author":"M Sabihi","year":"2020","unstructured":"Sabihi M, B\u00f6ttcher M, Pelczar P et al. Microbiota-dependent effects of IL-22. Cells. 2020;9:2205. https:\/\/doi.org\/10.3390\/cells9102205.","journal-title":"Cells."},{"key":"9007_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12934-017-0762-1","volume":"16","author":"Y Lin","year":"2017","unstructured":"Lin Y, Krogh-Andersen K, Hammarstr\u00f6m L et al. Lactobacillus delivery of bioactive interleukin-22. Microb Cell Factories. 2017;16:148. https:\/\/doi.org\/10.1186\/s12934-017-0762-1.","journal-title":"Microb Cell Factories."},{"key":"9007_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature13564","volume":"514","author":"X Wang","year":"2014","unstructured":"Wang X, Ota N, Manzanillo P et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014;514:237\u2013241. https:\/\/doi.org\/10.1038\/nature13564.","journal-title":"Nature."},{"key":"9007_CR27","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s41385-022-00577-w","volume":"15","author":"Q Zhu","year":"2022","unstructured":"Zhu Q, Korenfeld D, Suarez-Fueyo A et al. Epithelial dysfunction is prevented by IL-22 treatment in a citrobacter rodentium-induced colitis model that shares similarities with inflammatory bowel disease. Mucosal Immunol. 2022;15:1338\u20131349. https:\/\/doi.org\/10.1038\/s41385-022-00577-w.","journal-title":"Mucosal Immunol."},{"key":"9007_CR28","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1136\/gutjnl-2022-327025","volume":"71","author":"S Danese","year":"2022","unstructured":"Danese S, Solitano V, Jairath V et al. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). Gut. 2022;71:2380\u20132387. https:\/\/doi.org\/10.1136\/gutjnl-2022-327025.","journal-title":"Gut."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09007-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:02:38Z","timestamp":1750788158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09007-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9007"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09007-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.S. and T.D.S. are consultants for Cytoki Pharma. S.D\u2019A has received service fees from Cytoki Pharma, Domp\u00e8, Enthera, Ferring, Violicom, Novapep, Surrozen. A.D. has received honoraria as a speaker and\/or advisory board member from AbbVie, Janssen, Pfizer, Takeda, and Tillots Pharma. A.L.K., R.J. and M.v.d.B. are employees of Cytoki Pharma. S.D. received honoraria as a speaker, consultant, and\/or advisory board member from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, and Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies in animals have been carried out in accordance with European Union legislation and have received ethical approval from the Italian Ministry of Health. The study involving human subjects has been carried out in accordance with the Declaration of Helsinki and was approved by the Central Denmark Region Ethics Committee (j. no. 1-10-72-362-21).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants in the study involving human subjects after the nature and possible consequences of the study were explained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}